AASLD Voice of China | Dr. Liang Peng’s Team: Release of Clinical and Basic Research Results on Multiple Hepatitis B Studies, Preliminary Confirmation

AASLD Voice of China | Dr. Liang Peng’s Team: Release of Clinical and Basic Research Results on Multiple Hepatitis B Studies, Preliminary Confirmation

2023.12.22
From November 10th to 14th, 2023, the annual international highlight event in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, is being held in Boston, USA. Dr. Liang Peng's team from the Third Affiliated Hospital of Sun Yat-sen University has had multiple research results included in the conference. One randomized controlled trial evaluated the safety and effectiveness of tenofovir alafenamide fumarate (TAF) treatment for hepatitis B "healthy" carriers, and preliminary results indicate that TAF is safe for this population, with a rapid decrease in HBV DNA after 24 weeks of antiviral therapy, especially in the HBeAg-negative group where the HBV DNA undetectable rate is high [1].
AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target

AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target

2023.12.21
From November 10th to 14th, the annual highlight of hepatology, the American Association for the Study of Liver Diseases (AASLD) 2023, was grandly held in Boston, USA. With over 200 abstracts from Chinese experts and scholars selected for oral presentations or poster sessions, the achievements were commendable. Congratulations to all! Dr. Fengmin Lu's team from Peking University has three contributions to this event (1 oral presentation and 2 posters). Today, we'll share insights from one of the posters presented on the first day, November 10th, revealing the team's academic prowess. The research discovered that the A1762T/G1764A mutation, by affecting the HBV transcriptome, can promote HBV replication (Abstract Number: 1514-C).
AASLD Review | New Therapies for Hepatitis B: Vebicorvir, Selgantolimod, Bepirovirsen, Therapeutic Vaccines, and More

AASLD Review | New Therapies for Hepatitis B: Vebicorvir, Selgantolimod, Bepirovirsen, Therapeutic Vaccines, and More

2023.12.21
Currently, some patients with chronic hepatitis B (CHB) can achieve clinical cure through interferon-based antiviral treatment. To pursue clinical cure for a larger population, there is a flurry of activity in the development of new drugs. Six studies on new therapies for hepatitis B were selected for presentation at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, to be discussed in the "Hepatitis B: New Therapies for HBV and HDV" session. Hepatology Digest has compiled this information for interested readers, and the session is scheduled for online access on November 12th at 8:30 AM local time.